Hideyuki Takeshima
Overview
Explore the profile of Hideyuki Takeshima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoshida K, Watanabe K, Nishimura T, Ikushima H, Ohara S, Takeshima H, et al.
Anticancer Res
. 2024 Dec;
45(1):295-305.
PMID: 39740836
Background/aim: New treatment agents for advanced non-small cell lung carcinoma (NSCLC) have improved overall survival (OS) in the last 20 years. Nevertheless, treatment strategies for patients with NSCLC and pulmonary...
2.
Sasaki A, Takeshima H, Yamashita S, Ichita C, Kawachi J, Naito W, et al.
J Gastroenterol
. 2024 Mar;
59(6):442-456.
PMID: 38499886
Background: Nodular gastritis (NG) is characterized by marked antral lymphoid follicle formation, and is a strong risk factor for diffuse-type gastric cancer in adults. However, it is unknown whether aberrant...
3.
Nishiyama K, Nishinakamura H, Takeshima H, Yuyu L, Takeuchi C, Hattori N, et al.
PLoS One
. 2023 Oct;
18(10):e0290034.
PMID: 37797047
Precise analysis of tissue DNA and RNA samples is often hampered by contaminating non-target cells whose amounts are highly variable. DNA methylation profiles are specific to cell types, and can...
4.
Takeuchi C, Yamashita S, Liu Y, Takeshima H, Sasaki A, Fukuda M, et al.
Gut
. 2023 Sep;
73(2):255-267.
PMID: 37751933
Objective: The presence of intestinal metaplasia (IM) is a risk factor for gastric cancer. However, it is still controversial whether IM itself is precancerous or paracancerous. Here, we aimed to...
5.
Arai N, Hattori N, Yamashita S, Liu Y, Ebata T, Takeuchi C, et al.
Breast Cancer Res Treat
. 2023 Jun;
201(2):317-328.
PMID: 37378696
Purpose: HER2-positive breast cancer has a high chance of achieving pathological complete response when HSD17B4, responsible for peroxisomal β-oxidation of very long-chain fatty acids (VLCFA) and estradiol, is methylation-silenced. Here,...
6.
Nishimura T, Sakatani T, Takeshima H, Matsuda S, Yoshizawa T, Usui K
Case Rep Oncol
. 2023 Feb;
15(3):868-873.
PMID: 36825096
Neurotoxicity is one of the more serious immune-related adverse events (irAEs) linked to immune checkpoint inhibitors and calls for prompt diagnosis and treatment. We describe a case of posttreatment anti-programmed...
7.
Shimizu T, Sugihara E, Takeshima H, Nobusue H, Yamaguchi R, Yamaguchi-Iwai S, et al.
Cells
. 2022 Nov;
11(22).
PMID: 36429043
Novel therapeutic targets are needed to better treat osteosarcoma, which is the most common bone malignancy. We previously developed mouse osteosarcoma cells, designated AX (accelerated bone formation) cells from bone...
8.
Ebata T, Yamashita S, Takeshima H, Yoshida H, Kawata Y, Kino N, et al.
Gynecol Oncol
. 2022 Oct;
167(3):513-518.
PMID: 36253303
Objective: To establish a quantitative method to evaluate the DNA methylation level of an immediate upstream region of major BRCA1 transcriptional start sites (TSSs), and to investigate whether methylation of...
9.
Ueda S, Yamashita S, Nakajima M, Kumamoto T, Ogawa C, Liu Y, et al.
Proc Natl Acad Sci U S A
. 2022 Jul;
119(31):e2123241119.
PMID: 35895679
Somatic mutations are accumulated in normal human tissues with aging and exposure to carcinogens. If we can accurately count any passenger mutations in any single DNA molecule, since their quantity...
10.
Fujii K, Takeshima H, Nishimura T, Sakatani T, Masuda Y, Morikawa T, et al.
Respir Med Case Rep
. 2022 May;
36:101591.
PMID: 35535320
A 58-year-old woman with cough and dyspnea who was suspected of having idiopathic interstitial pneumonia had been treated with corticosteroids and cyclosporine, but the symptoms had worsened. There were no...